Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation
Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation. // Clinical Lymphoma, Myeloma & Leukemia. – URL: https://www.sciencedirect.com/science/article/pii/S2152265026032921?dgcid=rss_sd_all
Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation. Clinical Lymphoma, Myeloma & Leukemia. https://www.sciencedirect.com/science/article/pii/S2152265026032921?dgcid=rss_sd_all
“Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation.” Clinical Lymphoma, Myeloma & Leukemia.
@article{article40972,
title = {Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation},
journal = {Clinical Lymphoma, Myeloma \& Leukemia},
url = {https://www.sciencedirect.com/science/article/pii/S2152265026032921?dgcid=rss_sd_all}
}